A
PSAPsa
Psa blood test 0.02 does not necessarily mean that metastases are present. ED drugs probably would not cause a
PSAPsa
Psa blood test elevation. At 0.02 a retest may not be unreasonable. Although the definition of biochemical recurrence after prostate cancer surgery is 0.2 ng/mL.
Prediction of disease recurrence is based on several
factorsFactor ix complex. Several investigators (including myself) have come up with patient friendly resources in understanding the chances of disease recurrence. These are often based on PSA level prior to treatment and biopsy/surgical pathology results.
Some helpful links are:
The Prostate Calculator which I helped developed: http://www.prostatecalculator.org/
and the MSKCC Prostate Nomogram: http://www.mskcc.org/mskcc/html/10088.cfm
Thank you for your question.
Sincerely,
Ashutosh (Ash) Tewari, MD
http://www.cornellroboticprostate.org
This forum is for information only. The contents, such as graphics, images, text, quoted information and all other materials ("Content") are provided for reference only, do not claim to be complete or exhaustive or to be applicable to any particular individual's medical condition. Users should always consult with a qualified and licensed physician or other medical care provider. Users are warned to follow the advice of their physicians without delay regardless of anything read in this forum. The Weill Cornell Prostate Cancer Institute assumes no duty to correct or update the Content nor to resolve or clarify any inconsistent information which may be a part of the Content. Reliance on any Content is solely at the User's risk. This forum may contain health or medically related materials considered sexually explicit. Users are warned that if they may be offended by such Content, an alternate source of information should be found. Publication of information or reference in forum to specific sources such as specific products, procedures, physicians, treatments, or diagnoses are for information only and are not endorsements of the Weill Cornell Prostate Cancer Institute.